Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04ISS
|
||||
| Former ID |
DIB002444
|
||||
| Drug Name |
SAR-1118
|
||||
| Synonyms |
Dual LFA-1/ICAM-1 inhibitors, Sunesis; Dual LFA-1/ICAM-1 inhibitors (inflammatory diseases), SARcode; Dual leukocytefunction-associated antigen-1/intracellular adhesion molecule-1 inhibitors (inflammatory diseases), SARcode
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Sunesis Pharmaceuticals Inc
|
||||
| Formula |
C29H24Cl2N2O7S
|
||||
| InChI |
InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
|
||||
| InChIKey |
JFOZKMSJYSPYLN-QHCPKHFHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Lymphocyte function-associated antigen 1 | Target Info | Inhibitor | [532142] | |
| ICAM-1 | Target Info | Inhibitor | [532815] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Cell adhesion molecules (CAMs) | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Leukocyte transendothelial migration | |||||
| Regulation of actin cytoskeleton | |||||
| Malaria | |||||
| Staphylococcus aureus infection | |||||
| HTLV-I infection | |||||
| Epstein-Barr virus infection | |||||
| Rheumatoid arthritis | |||||
| Viral myocarditishsa04064:NF-kappa B signaling pathway | |||||
| TNF signaling pathway | |||||
| African trypanosomiasis | |||||
| Influenza A | |||||
| Viral myocarditis | |||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Cell surface interactions at the vascular wall | |||||
| Integrin cell surface interactionsR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
| Integrin cell surface interactions | |||||
| Interferon gamma signaling | |||||
| WikiPathways | Focal Adhesion | ||||
| Integrin-mediated Cell Adhesion | |||||
| Integrin cell surface interactions | |||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
| Cell surface interactions at the vascular wallWP619:Type II interferon signaling (IFNG) | |||||
| IL1 and megakaryotyces in obesity | |||||
| Human Complement System | |||||
| Spinal Cord Injury | |||||
| Interleukin-11 Signaling Pathway | |||||
| RANKL/RANK Signaling Pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| Ref 523596 | ClinicalTrials.gov (NCT01421498) Safety and Efficacy Study of SAR 1118 to Treat Dry Eye. U.S. National Institutes of Health. | ||||
| Ref 542538 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7533). | ||||
| Ref 532142 | Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. | ||||
| Ref 532815 | Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.